依奇珠单抗与苏金单抗治疗中重度斑块状银屑病的匹配调整间接比较
本研究采用匹配调整间接比较(MAIC)方法,基于活性对照和安慰剂对照研究数据,比较依奇珠单抗与苏金单抗治疗中重度斑块状银屑病的疗效和生活质量。结果显示,在第12周,依奇珠单抗的PASI 90和PASI 100应答率显著高于苏金单抗,而DLQI 0/1应答率无显著差异。
要点
- 两组第12周DLQI 0/1应答率无显著差异。
核心结论
- 基于调整间接比较,依奇珠单抗在第12周的PASI 90和PASI 100应答率高于苏金单抗。
研究设计与样本
- 研究采用匹配调整间接比较,数据来源于依奇珠单抗和苏金单抗的活性对照(依那西普和乌司奴单抗)及安慰剂对照研究。
- 比较方法包括Bucher法和两种改良的Signorovitch法(SG total和SG separate),并使用通用逆方差Meta分析合并活性对照共同比较器的结果。
主要发现
- PASI 75结果在SG方法下相当,在BU方法下倾向于依奇珠单抗。
- 第12周DLQI 0/1应答率无显著差异。
关键数值与推荐
- 依奇珠单抗用法:第0周160 mg,随后80 mg每2周一次,前12周。
- 苏金单抗用法:第0、1、2、3、4周300 mg,随后300 mg每4周一次。
- 疗效指标包括PASI 75、PASI 90、PASI 100和DLQI 0/1应答率。
临床怎么用
- 对于中重度斑块状银屑病患者,依奇珠单抗在达到更高皮损清除(PASI 90/100)方面可能优于苏金单抗。
- 临床决策时需结合患者具体情况和间接比较的局限性综合考虑。
局限性
- 缺乏头对头随机对照研究,间接比较可能存在未测量的混杂因素。
- 比较基于不同研究的数据,需谨慎解释结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Head-to-head randomized studies comparing ixekizumab and secukinumab in the treatment of psoriasis are not available. OBJECTIVES: To assess efficacy and quality of life using matching-adjusted indirect comparisons for treatment with ixekizumab vs. secukinumab. METHODS: Psoriasis Area and Severity Index (PASI) improvement of at least 75%, 90% and 100% and Dermatology Life Quality Index (DLQI) 0/1 response rates for approved dosages of ixekizumab (160 mg at Week 0, then 80 mg every two weeks for the first 12 weeks) and secukinumab (300 mg at Weeks 0, 1, 2, 3 and 4, then 300 mg every 4 weeks) treatment were compared using data from active (etanercept and ustekinumab) and placebo-controlled studies. Comparisons were made using the Bucher (BU) method and two modified versions of the Signorovitch (SG) method (SG total and SG separate). Subsequently, results based on active treatment common comparators were combined using generic inverse-variance meta-analysis. RESULTS: In the meta-analysis of studies with active comparators, PASI 90 response rates were 12·7% [95% confidence interval (CI) 5·5-19·8, P = 0·0005], 10·0% (95% CI 2·1-18·0, P = 0·01) and 11·2% (95% CI 3·2-19·1, P = 0·006) higher and PASI 100 response rates were 11·7% (95% CI 5·9-17·5, P < 0·001), 12·7% (95% CI 6·0-19·4, P < 0·001) and 13·1% (95% CI 6·3-19·9, P < 0·001) higher for ixekizumab compared with secukinumab using BU, SG total and SG separate methods. PASI 75 results were comparable when SG methods were used and favoured ixekizumab when the BU method was used. Week 12 DLQI 0/1 response rates did not differ significantly. CONCLUSIONS: Ixekizumab had higher PASI 90 and PASI 100 responses at week 12 compared with secukinumab using adjusted indirect comparisons.
引用
- Warren RB, Brnabic A, Saure D, et al. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br J Dermatol. 2018. PMID: 29171861. doi:10.1111/bjd.16140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。